[1] Matarazzo MR, De Bonis ML, Strazzullo M, et al.Multiple binding of methyl-CpG and polycomb proteins in long-term gene silencing events[J]. J Cell Physiol,2007, 210(3):711-719.
[2] Fandy TE, Herman JG, Kerns P, et al.Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies[J]. Blood,2009, 114(13):2764-2773.
[3] Palii SS, Van Emburgh BO, Sankpal UT, et al.DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B[J]. Mol Cell Biol,2008,28(2):752-771.
[4] Mortusewicz O, Schermelleh L, Walter J, et al.Recruitment of DNA methyltransferase I to DNA repair sites[J]. Proc Natl Acad Sci U S A,2005,102(25):8905-8909.
[5] Aimiuwu J, Wang H, Chen P, et al.RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia[J]. Blood, 2012,119(22):5229-5238.
[6] Liu K, Wang YF, Cantemir C, et al.Endogenous assays of DNA methyltransferases: Evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo[J]. Mol Cell Biol,2003,23(8):2709-2719.
[7] Bejar R, Lord A2, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients[J]. Blood,2014,124(17):2705-2712.
[8] Giachelia M, D'Alò F, Fabiani E, et al. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine[J]. Leuk Res,2011, 35(4):465-471.
[9] Desmond JC, Raynaud S, Tung E, et al.Discovery of epigenetically silenced genes in acute myeloid leukemias[J]. Leukemia,2007,21(5):1026-1034.
[10] Li H, Chiappinelli KB, Guzzetta AA, et al.Immune re-gulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers[J]. Oncotarget,2014,5(3):587-598.
[11] Goodyear OC, Dennis M, Jilani NY, et al.Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)[J]. Blood,2012,119(14):3361-3369.
[12] Bryan J, Jabbour DE,Prescott H, et al.Current and future management options for myelodysplastic syndromes[J].Drugs,2010,70(11):138l-1394.
[13] Lee JH, Choy ML, Ngo L,et al.Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair[J]. Proc Natl Acad Sci U S A,2010,107(33):14639-14644.
[14] Taby R, Issa JP.Cancer epigenetics[J]. CA Cancer J Clin,2010,60(6):376-392.
[15] Voso MT, Santini V, Finelli C, et al.Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes[J]. Clin Cancer Res,2009,15(15):5002-5007.
[16] Issa JP, Garcia-Manero G, Huang X, et al.Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia[J]. Cancer,2015,121(4): 556-561.
[17] Prebet T, Vey N.Vorinostat in acute myeloid leukemia and myelodysplastic syndromes[J]. Expert Opin Investig Drugs,2011,20(2):287-295.
[18] Bertino EM, Otterson GA.Romidepsin: a novel histone deacetylase inhibitor for cancer[J]. Expert Opin Investig Drugs,2011,20(8):1151-1158.
[19] Jabbour E, Garcia-Manero G.Deacetylase inhibitors for the treatment of myelodysplastic syndromes[J]. Leuk Lymphoma,2015,56(5):1205-1212
[20] Dutt S, Narla A, Lin K, et al.Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells[J]. Blood,2011,117(9):2567-2576.
[21] Wei S, Chen X, McGraw K, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion[J]. Oncogene,2013,32(9):1110-1120.
[22] Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al.Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype[J]. Nat Med,2010,16(1):49-58.
[23] Venner CP, Woltosz JW, Nevill TJ, et al.Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome[J]. Haematologica,2013,98(3):409-413.
[24] Wei S, Chen X, Rocha K, et al.A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide[J]. Proc Natl Acad Sci U S A,2009,106(31):12974-12979.
[25] Schneider RK, Ademà V, Heckl D, et al.Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS[J]. Cancer Cell,2014,26(4):509-520.
[26] Fink EC, Ebert BL.The novel mechanism of lenalidomide activity[J]. Blood,2015,126(21):2366-2369.
[27] Yip BH, Pellagatti A, Vuppusetty C, et al.Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts[J]. Leukemia,2012,26(9):2154-2158.
[28] Caceres G, McGraw K, Yip BH, et al. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients[J]. Proc Natl Acad Sci U S A,2013,110(40):16127-16132.
[29] Narla A, Dutt S, McAuley JR, et al. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis[J]. Blood,2011,118(8):2296-2304.
[30] Ximeri M, Galanopoulos A, Klaus M, et al.Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion[J]. Haematologica,2010,95(3):406-414.
[31] Garcia-Manero G, Fenaux P, Al-Kali A, et al.Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethyla-ting drugs(ONTIME): a randomised, controlled, phase 3 trial[J]. Lancet Oncol,2016,17(4):496-508.
[32] Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents[J]. Leukemia,2014,28(6):1280-1288.
[33] Mies A, Hermine O, Platzbecker U.Activin Receptor Ⅱ Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts[J]. Curr Hematol Malig Rep,2016.
[34] Benetatos CA, Mitsuuchi Y, Burns JM, et al.Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models[J]. Mol Cancer Ther,2014,13(4):867-879.
